Press enter to search
Close search
Open Menu


News and information on state and federal pharmacy legislation and advocacy.

Pharmacists continue to top annual Gallup Poll as trustworthy professionals

On the heels of Gallup's finding that pharmacists are highly valued, NACDS urges fair reimbursement and better access to pharmacy care.

Walgreens undertakes relief efforts in Puerto Rico

The retailer has kicked off a donation drive in Puerto Rico and southern Florida, as well as made product donations to local emergency shelters.

NACDS ' 30-second message recognizes pharmacists’ dedication to serve as part of opioid abuse prevention and pain care.

The proposed rule would repeal the approach that states use to demonstrate and ensure compliance with federal access requirements, NACDS said in its comments to the Centers for Medicare and Medicaid Services.

Eight pharmacy groups welcomed a letter from over 80% of committee members to the Trump administration, urging closure of a Medicare regulatory loophole to remedy DIR fees.

The Boise, Idaho-based retailer has rolled out DisposeRx to its more than 1,800 pharmacies in 24 states across its various banners.

Pharmacy organizations are urging the Senate Finance Committee to swiftly take action on DIR fee reform.

The legislation addresses the opioid epidemic, while remaining sensitive to chronic pain sufferers.

Texas has become the 23rd state to enact NACDS-backed e-prescribing legislation.

NCPA, NACDS, NASP, APhA, FMI and NGA united to send President Trump a letter advocating for immediate action on DIR pharmacy fee reform.

NACDS’ new policy recommendations for opioid abuse prevention build on existing initiatives to prevent abuse and to protect pain treatment.

Sen. Ron Wyden, D-Ore., and Michele Belcher, a National Community Pharmacists Association board member and owner of Grants Pass Pharmacy, discussed efforts to reduce drug prices that are underway in the Senate Finance Committee.

NACDS has issued an action alert, urging Congress to provide DIR fee relief through the Phair Pricing Act.

NACDS, and NCPA reacted with disapproval after a final drug pricing rule excluded reforms to pharmacy DIR fees.

Show More